Goldman Sachs Upgrades CG Oncology to Buy, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Johnson upgraded CG Oncology (NASDAQ:CGON) from Neutral to Buy and increased the price target from $43 to $50.

May 14, 2024 | 12:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CG Oncology was upgraded by Goldman Sachs from Neutral to Buy, with a price target increase from $43 to $50, indicating a positive outlook on the stock.
Analyst upgrades, especially from reputable firms like Goldman Sachs, can significantly influence investor sentiment and stock prices. The upgrade from Neutral to Buy suggests a strong confidence in CG Oncology's future performance, potentially leading to increased investor interest and a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100